Indaptus Therapeutics, Inc.
INDP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.17 | -4.22 | 2.77 | -0.46 |
| FCF Yield | -5.59% | -3.24% | -3.95% | -1.73% |
| EV / EBITDA | -14.31 | -24.47 | -21.86 | -79.44 |
| Quality | ||||
| ROIC | -381.38% | -133.68% | -57.68% | -21.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.87 | 0.91 | 1.46 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 8.07% | -1.17% | -17.32% | -239.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.38 | 0.81 | 0.64 | 5.04 |
| Interest Coverage | 0.00 | 0.00 | -25.35 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -432,154.54 | -229,121.07 | -282,473.52 | -660,821.96 |